Menopause Wise

Based on the best available evidence, “Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society” has just been released. Each section of the previous paper was reviewed by an Advisory Panel of seventeen clinicians and researchers expert in this area of women’s health using new studies and findings. The paper was then approved by the NAMS Board of Trustees. Specifically, the sections on Breast cancer, cognitive aging/decline and dementia, coronary heart disease, stroke, and discontinuance received special attention in light of recently published literature. New sections have been added on hormone therapy (HT) and ovarian and lung Cancer. “From a clinical perspective, the latest NAMS position statement on HT considers the current best practice of medicine. The Panel of world famous authorities clarified a broad spectrum of topics related to HT benefits and risks for postmenopausal women,” said Margery L.S. Gass, MD, NCMP, NAMS Executive Director.

This NAMS position statement has been endorsed by the American Medical Women’s Association (AMWA), the Asociación Mexicana para el Estudio del Climaterio (AMEC), The Endocrine Society,HealthyWomen (formerly the National Women’s Health Resource Center), the National Association of Nurse Practitioners in Women’s Health (NPWH), and the Society of Obstetricians and Gynaecologists of Canada (SOGC),all of which had representatives participating fully in the editorial process.

Click here to read the position paper in full: